Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_assertion type Assertion NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_head.
- NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_assertion description "[Moreover, dominant negative cross talk between ectopic wild-type p53 and recently identified dominant p53 mutants and splice variants of p63 and p73--which are frequently overexpressed in ovarian cancers--could seriously compromise the effectiveness of p53 gene therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_provenance.
- NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_assertion evidence source_evidence_literature NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_provenance.
- NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_assertion SIO_000772 12850192 NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_provenance.
- NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_assertion wasDerivedFrom befree-2016 NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_provenance.
- NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_assertion wasGeneratedBy ECO_0000203 NP401166.RA9KrmVnAx1iELGlmmimnCPabTj2r3Kat5jbRSD1u3lFg130_provenance.